AshlandASH
Recorded

Ashland 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 19 minParticipants17

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day. Thank you for standing by. Welcome to the Ashland third quarter conference earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your first speaker today, Sandy Klugman, Director of Investor Relations. Thank you, Sandy. Thank you.

Sandy KlugmanDirector of Investor Relations

Hello, everyone. Welcome to Ashland's third quarter fiscal year 2026 earnings conference call and webcast. My name is Sandy Klugman. I am Ashland's Director of Investor Relations. Joining me on the call today are Guillermo Novo, Chair and CEO, William Whitaker, CFO, as well as our business unit leaders, Alessandra Faccin, Life Sciences and Intermediates, Jim Minicucci, Personal Care, and Dago Cáceres, Specialty Additives. Please note that we will be referencing slides during today's call. We encourage you to follow along with the webcast materials available at ashland.com under Investor Relations. Please turn to slide two. As a reminder, today's presentation contains forward-looking statements regarding our fiscal 2026 outlook and other matters as detailed on slide two and in our Form 10-Q. These statements are subject to risks and uncertainties that could cause future results to differ materially from today's projections.

Sandy KlugmanDirector of Investor Relations

We believe any such statements are based on reasonable assumptions. There's no assurance these expectations will be achieved. We will also reference certain adjusted financial metrics, both actual and projected, which are non-GAAP measures. We present these adjusted figures to provide additional insight into our ongoing business performance. GAAP reconciliations are available on our website in the appendix of these slides. I'll now hand the call over to Guillermo for his opening remarks.

Guillermo NovoChair and CEO

Thanks, Sandy. Welcome to everyone joining us. Please turn to slide five. Overall, we delivered a strong third quarter that reflected strong demand, disciplined commercial execution, and healthy free cash flow generation. Sales increased across all business units. Our performance was in line with the expectations we outlined at the beginning of the quarter. These results reflect the team's strong execution and reinforce the momentum we are building across the businesses. Life Sciences delivered double-digit sales growth, benefiting from broad contributions across pharma end markets and ongoing momentum within our globalized and innovate strategies. Pharma achieved its fifth consecutive quarter of volume growth, supported by strength in high-purity excipients, injectables, and innovation growth momentum. Personal Care generated another quarter of solid performance, led by biofunctional actives, high single-digits growth in skincare, and favorable contributions from hair care and Microbial Protection.

Guillermo NovoChair and CEO

Performance reflected healthy growth across end markets and major regions, supported by strong customer engagement and innovation adoption. Specialty Additives delivered encouraging sales growth in line with our expectations. Strength in coatings and performance specialties was primarily driven by market share gains, reflecting strong commercial execution by the team. Regionally, most markets improved compared to prior year. Intermediates delivered higher sales, supported by improving merchant sales, driven by higher NMP demand in North America, EV battery, and energy storage applications. Operationally, our third quarter results reflected continued progress on manufacturing performance with further opportunities to improve. We remain focused on targeted investments and disciplined execution and expect continued progress in the fourth quarter as the benefits of these actions build.

Guillermo NovoChair and CEO

We also generated strong cash flow during the quarter through disciplined working capital management and ended the quarter with a net leverage of 2.4x, returning to our long-term target range and strengthening our ability to invest in growth and innovation. Please turn to slide six. Our results demonstrated the strength of our execution and the benefit of the actions we have taken across the portfolio. Sales increased 7% year-over-year, reflecting broad-based growth across the portfolio. Profitability was impacted by production challenges encountered earlier in the fiscal year. Results improved sequentially and were largely in line with our expectations. We continued to make steady progress across the manufacturing network and on our strategic priorities. Our teams remain focused on commercial execution, pricing realization, and cost discipline. Pricing actions continued to gain traction, offsetting higher raw material costs while maintaining strong customer relationships. Please turn to slide seven.

Guillermo NovoChair and CEO

Slide seven illustrates the breadth of our growth and the quality of our earnings profile. First, our consumer-focused businesses, Life Sciences and Personal Care, continue to generate attractive margins supported by resilient demand, innovation, and favorable mix. Second, Innovate and Globalize strategies continue to deliver measurable results with accelerated momentum in higher value application across the portfolio. Through the first nine months of the year, Innovate has exceeded its full-year target, while Globalize has already achieved its full-year target and continues to deliver strong results across the platforms. Third, while margins continue to reflect earlier production rate challenges and cost pressures, the actions we have taken across pricing, manufacturing, and commercial executions continue to gain traction. As a result, we are well-positioned for further profitability improvement in the fourth quarter.

Guillermo NovoChair and CEO

Before turning the call over to William, I also want to take a moment to share that yesterday we announced a cooperation agreement with Ancora, an Ashland shareholder, with whom we have had constructive dialogue. Under this agreement, we are welcoming Peter Thomas and Allen Spizzo to the Ashland board as independent directors. Both bring significant executive and financial experience in specialty chemicals, and we believe their perspectives will support our continued focus on creating value for our shareholders. The board is also forming a capital allocation advisory committee to bring additional rigor and objectivity to our capital allocation strategy and planning. We value ongoing engagement with our shareholders and look forward to working collaboratively with Peter, Allen, and the rest of the board as we continue to execute our strategy. Let me leave you with three key takeaways before we get into the financials.

Guillermo NovoChair and CEO

Demand remained healthy across our core businesses. Our innovate and globalize initiatives continue to generate meaningful growth, and we continue to make progress in addressing the operational challenges we have discussed throughout the year. These are encouraging signs for the business and reinforce our confidence in the opportunities ahead. Now I'd like to turn over the call to William to provide a more detailed view of the third quarter financial performance.

William WhitakerCFO

William? Thank you, Guillermo. Please turn to slide nine.

William WhitakerCFO

Third quarter sales were $497 million, up 7% versus the prior year, driven primarily by volume growth across all business units. Volumes increased 6% across the portfolio, led by continued strength in Life Sciences and Personal Care, while Specialty Additives returned to growth and Intermediates benefited from improving merchant demand. Pricing increased approximately 1% year-over-year, led by Life Sciences and Specialty Additives, reflecting sequential improvement of approximately 300 basis points. Foreign exchange contributed approximately $3 million, or 1%, to sales. Adjusted EBITDA was $109 million, compared to $113 million in the prior year quarter. Growth in Life Sciences and Personal Care was more than offset by lower earnings in Specialty Additives and Intermediates.

William WhitakerCFO

Profitability continued to reflect the impact of lower production rates earlier in the year and the normalization of incentive compensation from a low base in the prior year. These factors were partially offset by higher volumes, favorable mix, and pricing actions. Sequentially, profitability improved as operating performance gradually improved and commercial actions gained traction across the portfolio. We expect a further step-up in profitability during the fourth quarter. Adjusted EBITDA margin was 21.9%, compared to 24.4% in the prior year quarter, reflecting these dynamics. Adjusted earnings per share, excluding amortization expense, was $1.02 compared to $1.04 in the prior year quarter. Cash generation remained a significant strength during the quarter. Ongoing free cash flow totaled $103 million, compared with $108 million in the prior year quarter, or representing a conversion above 90%.

William WhitakerCFO

Inventory is down nearly $80 million fiscal year to date, supporting strong cash generation and positioning us for improved absorption and reduced inventory-related margin headwinds going forward. We ended the quarter with $936 million of available liquidity and net leverage of 2.4 times, returning to our long-term target range. During the quarter, we also refinanced our credit agreement, extending maturities on attractive terms and further strengthening our financial flexibility. The balance sheet remains a competitive advantage, providing flexibility to support operations, invest in strategic priorities, and maintain disciplined capital allocation. With that, I'll turn the call over to our business unit leaders for a closer look at segment performance. Alessandra, over to you for Life Sciences.

Alessandra FaccinSenior VP and General Manager of Life Sciences and Intermediates

Thank you, William. Good morning, everyone. Please turn to slide 10 for Life Sciences. Life Sciences delivered another strong quarter, with sales up $180 million, up 11% versus the prior year period. Performance was driven by higher sales volumes, led by broad-based strength across pharma applications. Pharma achieved double-digit sales growth and delivered its sixth consecutive quarter of year-over-year volume gains. Demand remained healthy across all regions and product categories, including continued strength in high-purity excipients and injectables. We also benefit from customer order timing and supply chain normalization during the quarter. Adjusting for those factors, underlying demand trends remain strong and consistent with our expectations. Pricing contributed positively to results as commercial actions began to gain traction during the quarter with full run rate realization expected in the fourth quarter. Foreign exchange contributed approximately $1 million to sales during the quarter.

Alessandra FaccinSenior VP and General Manager of Life Sciences and Intermediates

Injectables continued to outperform in the third quarter, delivering exceptional growth aligned with our globalized strategy. Performance was driven by the accelerating adoption of Ashland's high-purity differentiated excipient portfolio. Strong customer demand, a growing development pipeline, and increasing new product adoption support a strong outlook. We also announced the groundbreaking of our new tablet coating manufacturing facility in India, another important step in our globalized strategy. Following recent investments in Brazil, this expansion continues to strengthen our regional manufacturing footprint and position us to better serve customers in some of the fastest-growing pharma markets in the world. Turning to innovation, our recently launched products continue to drive above-market growth, led by low-nitrite oral solid dosage excipients and high-purity injectable and bioprocessing products. Strong customer adoption validates Ashland's strategy of investing in differentiated technologies that address increasingly complex formulation and regulatory requirements.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day